A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT03864627. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Multicentre Phase 2 Study to Evaluate the Safety and Tolerability of Subcutaneous MOR106 Administered Concomitantly With Topical Corticosteroids for Eight Weeks, in Adult Subjects With Moderate to Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To investigate the safety and tolerability of repeated subcutaneous (s.c.) doses of MOR106 administered concomitantly with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Study identification
- NCT ID
- NCT03864627
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2019 (Actual)
- Primary completion
- Feb 27, 2020 (Actual)
- Completion
- Feb 27, 2020 (Actual)
- Last update posted
- Jan 5, 2021
2019 – 2020
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| First OC Dermatology | Fountain Valley | California | 92708 | — |
| Marvel Research, LLC | Huntington Beach | California | 92647 | — |
| LA Universal Research Center, Inc. | Los Angeles | California | 90057 | — |
| MedDerm Associates | San Diego | California | 92103 | — |
| Encore Medical Research | Hollywood | Florida | 33021 | — |
| Advanced Research Institute of Miami LLC | Homestead | Florida | 33030 | — |
| Vista Health Research | Miami | Florida | 33185 | — |
| Arlington Dermatology | Rolling Meadows | Illinois | 60008 | — |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | 46250 | — |
| DS Research | Louisville | Kentucky | 40241 | — |
| Greenwich Village Dermatology | New York | New York | 10012 | — |
| Center for Clinical Studies | Houston | Texas | 77004 | — |
| Progressive Clinical Research | San Antonio | Texas | 78229 | — |
| Center for Clinical Studies | Webster | Texas | 77598 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03864627, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2021 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03864627 live on ClinicalTrials.gov.